NeoMedigen’s Announces Groundbreaking Advances in Skin Care
(firmenpresse) - NeoMedigen’s Announces Groundbreaking Advances in Skin Care
Hamilton, Bermuda July 18, 2013 – NeoMedigen Limited, a public company traded on the Berlin Exchange under Ticker Symbol 6NM, announced today that it has has made outstanding advances in anti-aging by pursuing groundbreaking new research on the links between aging and DNA damage in the skin.
The skin’s aging process is programmed by an individual’s DNA blueprint. For the skin, aging manifests as wrinkling, dark spots, loss of firmness and moisture. DNA is constantly being damaged over time by adverse factors such as inflammation and stress. The two main causes of DNA damage to the skin are UV rays and reactive oxygen species free radicals ( ROS). When DNA is damaged, it fails to correctly transmit the genetic information for normal skin function at cellular and tissue levels. This is the main cause of skin aging.
NeoMedigen has discovered a proprietary compund called “NeoDerm5” that accelerates the repair of DNA damage to skin. NeoDerm 5 can be administered as as a topical cream or in a capsule form. The substance has demonstrated effectiveness at the cellular level in boosting and promoting the repair mechanisms for each type of skin damage- by UV rays and by free-radicals. Based on its expertise accumulated through research on this type of skin aging and deterioration, NeoMedigen is developing key therapeutic dermatology and aesthetic dermatology formulations for use in prescription and OTC products. The total combined global market for these indications is estimated at some US $55.8 Billion per annum.
NeoMedigen is now actively pursuing fundamental dermatological research with universities that specialize in conducting clinical trials in this field. Through its research the Company intends to become a worldwide skincare pioneers in effective DNA repair technologies.
About Neomedigen Limited
NeoMedigen Limited is a Bermuda based biopharmaceutical company focused on discovering and developing proprietary, orally available, small molecule drugs with the potential to treat diseases associated with ageing, including metabolic diseases such as Type 2 Diabetes, Alzheimer’s and cardiovascular diseases. NeoMedigen is committed to improving the quality of human life by enabling people to do more, feel better and live longer. The company's headquarters are in Devonshire, Bermuda. For company information including a copy of this announcement and details of the company’s updated product development pipeline, visit www.neomedigen.com .
Cautionary statement regarding forward-looking statements
The company cautions investors that any forward-looking statements or projections made by the company, including those made in this Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect the Group's operations are described under 'Risk factors' in the 'Business Review' in the company's website.
This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of NeoMedigen Linited
Investors and security holders are urged to read each of these documents carefully when they are available.
In addition, investors and security holders will be able to obtain free copies of these documents by contacting the Investor Relations departments of NeoMedigen Limited.
Contact: info(at)neomedigen.com
Leseranfragen:
NeoMedigen Limited
35 Crow Lane East Broadway
Devonshire HM19
Bermuda
Telefon: +1-205-478-1110
Fax: +1-205-478-1110
E-Mail: pwhite(at)neomedigen.com
" alt="Orvana Reports Suspension of its Leach-Precipitation-Flotation Plant at its UMZ Mine
Datum: 18.07.2013 - 08:56 Uhr
Sprache: Deutsch
News-ID 279521
Anzahl Zeichen: 3666
contact information:
Town:
Wien
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 207 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NeoMedigen’s Announces Groundbreaking Advances in Skin Care
"
steht unter der journalistisch-redaktionellen Verantwortung von
NeoMedigen Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
